| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
University of Cambridge and Cancer Research UK Department of Oncology, CIMR, Hills Road, Cambridge, CB2 2XY, United Kingdom
We described previously a thyroid phenotype for transgenic mice expressing an activated Ret oncogene driven from a human calcitonin promoter. Medullary thyroid carcinomas (MTC), a tumor of the thyroid parafollicular C cells, occur in this transgenic line with a pathology analogous to that seen in patients with multiple endocrine neoplasia type 2 (MEN2). When the transgene was introgressed onto four different genetic backgrounds, between 0 and 98% of transgenic progeny developed thyroid tumors by 10 months of age, indicating that tumor penetrance could be modulated by genetic background. Furthermore, tumors on the CBA/ca and C57BL/6J backgrounds were significantly larger than those arising in BALB/c transgenic mice. These results are relevant to human MEN2 disease, because this model system may be used to study genes modifying thyroid tumor penetrance in the dominantly inherited human cancer syndrome.
This article has been cited by other articles:
|
|
 |
|
  S. Ruiz-Llorente, C. Montero-Conde, R. L. Milne, C. M. Moya, A. Cebrian, R. Leton, A. Cascon, F. Mercadillo, I. Landa, S. Borrego, et al. Association Study of 69 Genes in the Ret Pathway Identifies Low-penetrance Loci in Sporadic Medullary Thyroid Carcinoma Cancer Res., October 1, 2007; 67(19): 9561 - 9567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. B. Knostman, S. M. Jhiang, and C. C. Capen Genetic Alterations in Thyroid Cancer: The Role of Mouse Models Vet. Pathol., January 1, 2007; 44(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Carniti, S. Belluco, E. Riccardi, A. N. Cranston, P. Mondellini, B. A.J. Ponder, E. Scanziani, M. A. Pierotti, and I. Bongarzone The RetC620R Mutation Affects Renal and Enteric Development in a Mouse Model of Hirschsprung's Disease Am. J. Pathol., April 1, 2006; 168(4): 1262 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Montani, A M Schmitt, S Schmid, T Locher, P Saremaslani, P U Heitz, P Komminoth, and A Perren No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma Endocr. Relat. Cancer, December 1, 2005; 12(4): 1011 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Read, P. J. Goodfellow, E. R. Mardis, N. Novak, J. R. Armstrong, and R. L. Cagan A Drosophila Model of Multiple Endocrine Neoplasia Type 2 Genetics, November 1, 2005; 171(3): 1057 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Skinner, S. Kalyanaraman, S. D. Safford, R. O. Heuckeroth, W. Tourtellotte, D. Goyeau, P. Goodfellow, J. D. Milbrandt, and A. Freemerman A Human Yeast Artificial Chromosome Containing the Multiple Endocrine Neoplasia Type 2B Ret Mutation Does Not Induce Medullary Thyroid Carcinoma but Does Support the Growth of Kidneys and Partially Rescues Enteric Nervous System Development in Ret-Deficient Mice Am. J. Pathol., January 1, 2005; 166(1): 265 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Drosten, G. Hilken, M. Bockmann, F. Rodicker, N. Mise, A. N. Cranston, U. Dahmen, B. A. J. Ponder, and B. M. Putzer Role of MEN2A-Derived RET in Maintenance and Proliferation of Medullary Thyroid Carcinoma J Natl Cancer Inst, August 18, 2004; 96(16): 1231 - 1239. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
